Ronald Brenner
Psychiatry · Hempstead, NYNPI 1982631644
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,553 of the $203,470 with a category attached, or 77.4%. Alkermes, Inc. accounts for 76.5% of it on its own, with 19 other manufacturers making up the rest. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 530 payments — averaging $383.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$156K
- Johnson & Johnson$28K
- Teva Pharmaceuticals USA, Inc.$7K
- Boehringer Ingelheim$7K
- Neurocrine Biosciences, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$788
- plus $3K from 14 others
Across 1,234 payments — averaging $9157.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$3.5M
- AbbVie$1.4M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.2M
- Teva Pharmaceuticals USA, Inc.$904K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$726K
- Biogen$663K
- plus $2.9M from 22 others
What the payments were for
- Consulting fees$21,10810%
- Speaking & faculty fees$157,55377%
- Travel & lodging$11,0085%
- Food & beverage$13,5677%
- Education$2340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 205 | $155,688 |
| Johnson & Johnson | 77 | $28,486 |
| Teva Pharmaceuticals USA, Inc. | 77 | $6,773 |
| Boehringer Ingelheim | 6 | $6,616 |
| Neurocrine Biosciences, Inc. | 23 | $2,582 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $788 |
| AbbVie(2 entities) | 30 | $720 |
| Lundbeck LLC | 20 | $411 |
| Sunovion Pharmaceuticals Inc. | 17 | $351 |
| Bioxcel Therapeutics, Inc. | 5 | $281 |
| Otsuka America Pharmaceutical, Inc. | 15 | $280 |
| E.r. Squibb & Sons, L.L.C. | 6 | $156 |
| Luye Pharma (USA) Ltd. | 4 | $84 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Eisai Inc. | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Sage Therapeutics, LLC | 1 | $21 |
| Indivior Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$203,470 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 13 | $38,647 |
| Abilify MaintenaAripiprazole | 12 | $30,870 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $1,121 |
| Clonazepam | 35 | $725 |
| Divalproex Sodium | 21 | $396 |
| Bupropion Hcl SrBupropion Hcl | 15 | $274 |
| Olanzapine | 23 | $265 |
| Alprazolam | 14 | $257 |
| Doxepin Hcl | 21 | $196 |
| Escitalopram Oxalate | 19 | $187 |
| Quetiapine Fumarate | 29 | $140 |
| Zolpidem Tartrate | 25 | $128 |
| Fluoxetine Hcl | 12 | $117 |
| Lithium Carbonate | 11 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $28,486 | $38,64713 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $280 | $30,87012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Hempstead
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.